THREAD has acquired Modus Outcomes to combine high-technology and high-science in one platform designed to achieve higher-quality outcomes for research sponsors.
As clinical trials have grown more complex, so has effectively designing and implementing endpoints, which are now required in most research studies. With this acquisition, THREAD will bring together its eCOA technology platform with Modus’ services to provide global biopharma and contract research organiations (CROs) with a solution that optimises their decision-making for developing and commercialising new therapies.
Modus brings to THREAD deep expertise in qualitative research, advanced psychometric analysis and biostatistics, as well as consulting capabilities specialising in patient-centered outcomes strategies, including instrument design/selection and regulatory support.
John Reites, CEO of THREAD, said: “With more sophisticated scientific designs, larger global scale and a greater focus on highly targeted patient subpopulations, the biopharmaceutical industry is increasingly shifting to DCT’s. Combining Modus’ industry-leading scientific and eCOA expertise with our technology platform enhances our solutions and advances our mission of providing customers with one comprehensive platform, delivering five times more inclusive research and enabling 30% more efficient DCTs.”
Patrick Marquis, CEO of Modus Outcomes, said: “The shared values, approach and need for humanistic input to DCTs make this milestone acquisition a win for the industry. We are thrilled to join the THREAD team and work closely with customers and partners to achieve patient-centric outcomes.”